- Trials with a EudraCT protocol (11,739)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (909)
11,739 result(s) found for: II.
Displaying page 1 of 587.
EudraCT Number: 2018-003691-12 | Sponsor Protocol Number: TUD-CIRC01-071 | Start Date*: 2019-12-04 | ||||||||||||||||
Sponsor Name:Technische Universität Dresden | ||||||||||||||||||
Full Title: Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217 | ||||||||||||||||||
Medical condition: Colon cancer stage II | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005436-33 | Sponsor Protocol Number: CITUR08-HM/SONOCOL | Start Date*: 2009-01-21 | ||||||||||||||||
Sponsor Name:CHRU de TOURS | ||||||||||||||||||
Full Title: Apport de l’échographie doppler avec injection de contraste pour la prise en charge des cancers du col de l’utérus de stade IB et II traités par radiochimiothérapie concomitante | ||||||||||||||||||
Medical condition: Cancer du col de l'utérus épidermoïde ou adénocarcinome, de stade IB et IIA > à 4 cm ou IIB proximal | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002743-27 | Sponsor Protocol Number: TKT024EXT | Start Date*: 2004-12-23 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies INC. | |||||||||||||
Full Title: An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy | |||||||||||||
Medical condition: Mucopolysaccharidosis Type II (MPS II or Hunter Syndrome) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) SE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002316-23 | Sponsor Protocol Number: CKJX839C12001B | Start Date*: 2023-01-16 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who... | |||||||||||||
Medical condition: Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) NO (Ongoing) DE (Ongoing) NL (Ongoing) HU (Ongoing) GR (Ongoing) FR (Ongoing) SI (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004143-13 | Sponsor Protocol Number: SHP-609-302 | Start Date*: 2015-03-19 | ||||||||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | ||||||||||||||||||
Full Title: An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome... | ||||||||||||||||||
Medical condition: Hunter syndrome and cognitive impairment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014264-19 | Sponsor Protocol Number: 0908038 | Start Date*: 2010-01-14 | |||||||||||
Sponsor Name:Clinique Mutualiste Chirurgicale | |||||||||||||
Full Title: Prospective multicentric evaluation of a bladder preservation strategy using a combination of neoadjuvant chemotherapy with intensified MVAC (Méthotrexate + vinblastine + adriamicine + Cisplatine) ... | |||||||||||||
Medical condition: bladder infiltrative urothelium carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005754-23 | Sponsor Protocol Number: ASSTBS-FRADIO-SPA-2020 | Start Date*: 2021-04-06 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA Trial) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: prostate acinar adenocarcinoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001023-21 | Sponsor Protocol Number: DRL-17822/CD/004 | Start Date*: 2011-06-30 | |||||||||||
Sponsor Name:DR. REDDY'S LABORATORIES LIMITED | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients with Type II Hyperlipidemia | |||||||||||||
Medical condition: Hyperlipidemia Type II | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021600-24 | Sponsor Protocol Number: FEC | Start Date*: 2010-10-16 | |||||||||||
Sponsor Name:IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO | |||||||||||||
Full Title: FEC neo-adjuvant chemotherapy followed by weekly Taxol administration combined with Trastuzumab in II-III stage HER2 positive breast cancer patients.Fase II trial. | |||||||||||||
Medical condition: II/III stage HER2+ eligible for neoadjuvant chemotherapy breast cancer women | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011079-57 | Sponsor Protocol Number: BICG26UMCG-NIRF | Start Date*: 2009-05-28 | ||||||||||||||||
Sponsor Name:University Medical Center Groningen | ||||||||||||||||||
Full Title: Evaluation of Indocyanine Green (ICG) enhanced Near-InfraRed Fluorescence (NIRF) Imaging for Intra-Operative Sentinel Lymph Node (SLN) detection in Breast Surgery. | ||||||||||||||||||
Medical condition: Women above the age of 21 with core biopsy or cytology proven breast cancer stage I and II, eligible for lumpectomy and sentinel lymph node procedure | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003321-28 | Sponsor Protocol Number: LTS13769 | Start Date*: 2014-05-12 | ||||||||||||||||
Sponsor Name:Genzyme Corporation | ||||||||||||||||||
Full Title: An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of Avalglucosidase Alfa (NeoGAA, GZ402666) In Patients With Pom... | ||||||||||||||||||
Medical condition: Pompe disease (acid alpha-glucosidase deficiency) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) NL (Completed) DK (Completed) DE (Completed) FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000212-25 | Sponsor Protocol Number: HGT-HIT-046 | Start Date*: 2012-01-05 | |||||||||||
Sponsor Name:Shire HGT Inc | |||||||||||||
Full Title: An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction with Intravenous Elaprase® in Pediatric Pati... | |||||||||||||
Medical condition: Treatment of Hunter syndrome and cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-018188-29 | Sponsor Protocol Number: Calendula study | Start Date*: 2010-08-06 | ||||||||||||||||
Sponsor Name:Dept of Oncology | ||||||||||||||||||
Full Title: Randomised blinded trial of Calendula Officinalis compared with aqueos cream for the prevention of acute skin toxicity in relation to radiotherapy for breast cancer | ||||||||||||||||||
Medical condition: Patients operated for breast cancer who undergo postoperative adjuvant radiotherapy will be offered to participate in this randomized trial with the aim to reduce the risk of severe radiation skin ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: SE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002168-59 | Sponsor Protocol Number: AGLU017-02 | Start Date*: 2004-10-14 | |||||||||||
Sponsor Name:GENZYME | |||||||||||||
Full Title: An Open-Label, Multicenter, Multinational, Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid alpha- Glucosidase (rhGAA) Treatment in Patients > 6 and <... | |||||||||||||
Medical condition: Treatment for Type II Glycogenosis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000582-37 | Sponsor Protocol Number: CHOL00107 | Start Date*: 2007-09-21 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study of Colesevelam as Add-on Therapy in Patients with Familial Hypercholesterolaemia | |||||||||||||
Medical condition: Familial hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FR (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006808-11 | Sponsor Protocol Number: Studio Zevalin | Start Date*: 2006-08-11 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA | |||||||||||||
Full Title: Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma. | |||||||||||||
Medical condition: Patients with untreated follicular non-Hodgkin's lymphoma grade 1 or 2 according to REAL classification. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003595-38 | Sponsor Protocol Number: AT845-01 | Start Date*: 2020-11-20 | |||||||||||
Sponsor Name:Audentes Therapeutics, Inc. | |||||||||||||
Full Title: FORTIS: A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients with Late Onset Pompe Di... | |||||||||||||
Medical condition: Late Onset Pompe Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002848-41 | Sponsor Protocol Number: CAPL180A2207 | Start Date*: 2008-08-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemia | |||||||||||||
Medical condition: familial hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004047-25 | Sponsor Protocol Number: ALGMYL08718 | Start Date*: 2021-07-27 | |||||||||||
Sponsor Name:Sanofi(China) Investment Co Ltd, Shanghai Branch | |||||||||||||
Full Title: A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients with Infantile-Onset Pompe Disease with One Year Alglucosidase Alfa Treatment | |||||||||||||
Medical condition: Infantile-Onset Pompe Disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005552-11 | Sponsor Protocol Number: LTS12869 | Start Date*: 2022-03-07 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa. | |||||||||||||
Medical condition: Pompe disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
